NCT01119352View on ClinicalTrials.gov

AZD7687 Multiple Ascending Dose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
OverweightObese
Interventions
DRUG

AZD7687

Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.

DRUG

Placebo

Oral suspension, once daily. Totally 8 doses

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY